| Date | Form | Description | Docs | XBRL | Pages |
| 01/30/18 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
14 | |
| 01/30/18 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
14 | |
| 01/26/18 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
36 | |
| 01/23/18 | 8-K | Current report filing |
|
3 | |
| 01/09/18 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
148 |
| 12/12/17 | 8-K | Current report filing |
|
3 | |
| 11/22/17 | 8-K | Current report filing |
|
3 | |
| 11/17/17 | 8-K | Current report filing |
|
3 | |
| 11/17/17 | 8-K | Current report filing |
|
48 | |
| 11/17/17 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
45 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...